@nievamd

Oncologist, scientist, teacher & learner

 Pasadena, CA
Joined May 2016
  • Tweets213
  • Following443
  • Followers432
11Media
the-scientist.com/validation…. . Wonderful editorial by Rebecca Roberts on the problem of increasing exclusivity of cancer clinical trial participantion.

Validation and Analysis of 12,000 AI-Driven CAR T Designs in the Bits to Binders Competition | The...

Examine how large-scale CAR T-cell functional validation informs the efficacy of AI-driven protein binder design methodologies.

the-scientist.com
2
53
Grateful to have contributed to this important collaborative study with Dr. Jaclyn LoPiccolo and an incredible research team. Together, we explored the genetic factors that may shape risk and tumor biology in young-onset lung cancer. Swipe through for the key findings. 🧬🫁 pmc.ncbi.nlm.nih.gov/article…
3
13
1
28
3,030
sciencedirect.com/science/ar…
1
3
77
lungcancerstoday.com/post/we…

AACR 2026: Dr. Nieva Unpacks Data on Healthy Diets and Young-Onset Lung Cancer | Lung Cancers Today

Jorge Nieva, MD, of the University of Southern California, discusses AACR 2026 research on dietary patterns among patients with young-onset lung cancer.

lungcancerstoday.com
1
1
3
103
sciencedirect.com/science/ar…
72
Jorge Nieva retweeted
Mark@_MarkLeiserApr 23
Thank you to @nievamd @uscnorris for sharing insights into fascinating #AACR26 data. Could residue from pesticides be driving the 'hidden' #LungCancer epidemic among young nonsmokers? Find out here 👇
HemOnc Today@HemOncTodayApr 23
🍓🥬 ‘Counterintuitive’ data from #AACR26 suggests higher consumption of fruit, vegetables & whole grains may raise #LungCancer risk among younger nonsmokers. ❗ Exposure to #pesticide residue could be to blame. vist.ly/4zihh

‘Counterintuitive’: Healthy diet may raise lung cancer risk for younger nonsmokers

A study designed to investigate why lung cancer incidence has increased among younger nonsmokers over the past few decades yielded a surprising observation.Data from nearly 200 people diagnosed with...

healio.com
1
1
141
Please join me on March 17th at the Lung Cancer Living Room where we will be discussing clinical trials. events.go2.org/2026MarchLivi…

Help me support GO2 for Lung Cancer!

GO2 for Lung Cancer relentlessly confronts lung cancer on every front, every day, for everyone. Founded by patients and survivors, we are dedicated to increasing survival for those at risk, diagnos...

events.go2.org
2
4
117
substack.com/@danielanieva/n…
1
92
First-line #NSCLC care has evolved. In a conversation with @ADesaiMD (@ONealCancerUAB), @nievamd (@uscnorris) explains how patient priorities shape treatment intensification: bit.ly/4aTBGuG #NSCLC #CancerCare
2
4
435
Great work by one of our outstanding graduate students. authors.elsevier.com/c/1m5Ev…
1
3
217
Happy to see this important work on real world data of uncommon EGFR mutations publically available. link.springer.com/article/10…

Real-World Outcomes and Subsequent Treatment Patterns in Patients with Advanced Non-Small Cell Lung...

Oncology and Therapy - Osimertinib is recommended, alongside afatinib, as first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) with atypical mutations in the epidermal...

link.springer.com
1
2
120
🫁 As Lung Cancer Awareness Month continues, don't miss this insightful interview with @nievamd of @KeckMedicineUSC, who reflects on the importance of #LCAM, the cultural shift he's seen around lung cancer, and why screening is critical. ➡️ Watch: buff.ly/BsXjTto #lcsm
2
3
148
substack.com/@danielanieva/n…
1
51
Advancing new drugs to patients is important. But equally important is ensuring that drug toxicity is minimized. Very proud to have been part of this important study. jto.org/article/S1556-0864(2…

Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated...

Amivantamab plus lazertinib significantly improved progression-free and overall survival versus osimertinib in patients with previously untreated, EGFR-mutant advanced NSCLC. EGFR-targeted therapies...

jto.org
1
63
My daughter has launched a sub stack project and is proving herself to be a terrific writer. I invite you all to read it and subscribe if you want to see more. bordersunbound.substack.com
1
67
Very proud of Rahul Mudumba for completing this important pharmaco-economic analysis of ALK fusion lung cancer treatment. jmcp.org/doi/full/10.18553/j…

Real-world costs, treatment patterns, and clinical outcomes associated with treatments for advanced...

BACKGROUND: Alectinib, brigatinib, and lorlatinib are all preferred first-line (1L) therapies for anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC) in National Comprehens...

jmcp.org
1
1
6
186
💊 How do steroids impact survival in patients undergoing immunotherapy for NSCLC? 🫁 Don't miss this insightful interview with @nievamd of @KeckMedicineUSC, who discusses recent bedside-to-bench research that addressed the question. ➡️ Watch: buff.ly/FI2FBsS #lcsm
1
12
306
lungcancerstoday.com/post/be…

How Steroids Impact Survival in Patients Undergoing Immune Checkpoint Inhibitor Therapy for NSCLC |...

Jorge Nieva, MD, of USC, explains how steroids impact survival in patients undergoing immune checkpoint inhibitor therapy for non-small cell lung cancer (NSCLC).

lungcancerstoday.com
1
8
119
Greetings from Huntington Beach, CA.
1
4
26
1,333
Diving beyond EGFR in NSCLC with an excellent session chaired by @SchenkLab, featuring a stellar lineup of talks on KRAS, BRAF, ROS1, MET, RET, and more! With insights from @christinemphmd @drgandara @mihaela_aldea @nievamd @riess_md @OncLive #BTGLung2025 #LCSM #Oncology
3
1
20
2,652
Load more